What do the Universal Test and Treat trials tell us about the path to HIV epidemic control?

Diane Havlir, Shahin Lockman, Helen Ayles, Joseph Larmarange, Gabriel Chamie, Tendani Gaolathe, Collins Iwuji, Sarah Fidler, Moses Kamya, Sian Floyd, Janet Moore, Richard Hayes, Maya Petersen, Francois Dabis, (Universal Test, Treat Trials) UT3 Consortium, Diane Havlir, Shahin Lockman, Helen Ayles, Joseph Larmarange, Gabriel Chamie, Tendani Gaolathe, Collins Iwuji, Sarah Fidler, Moses Kamya, Sian Floyd, Janet Moore, Richard Hayes, Maya Petersen, Francois Dabis, (Universal Test, Treat Trials) UT3 Consortium

Abstract

Introduction: Achieving HIV epidemic control globally will require new strategies to accelerate reductions in HIV incidence and mortality. Universal test and treat (UTT) was evaluated in four randomized population-based trials (BCPP/Ya Tsie, HPTN 071/PopART, SEARCH, ANRS 12249/TasP) conducted in sub-Saharan Africa (SSA) during expanded antiretroviral treatment (ART) eligibility by World Health Organization guidelines and the UNAIDS 90-90-90 campaign.

Discussion: These three-year studies were conducted in Botswana, Zambia, Uganda, Kenya and South Africa in settings with baseline HIV prevalence from 4% to 30%. Key observations across studies were: (1) Universal testing (implemented via a variety of home and community-based testing approaches) achieved >90% coverage in all studies. (2) When coupled with robust linkage to HIV care, rapid ART start and patient-centred care, UTT achieved among the highest reported population levels of viral suppression in SSA. Significant gains in population-level viral suppression were made in regions with both low and high baseline population viral load; however, viral suppression gains were not uniform across all sub-populations and were lower among youth. (3) UTT resulted in marked reductions in community HIV incidence when universal testing and robust linkage were present. However, HIV elimination targets were not reached. In BCPP and HPTN 071, annualized HIV incidence was approximately 20% to 30% lower in the intervention (which included universal testing) compared to control arms (no universal testing). In SEARCH (where both arms had universal testing), incidence declined 32% over three years. (4) UTT reduced HIV associated mortality by 23% in the intervention versus control communities in SEARCH, a study in which mortality was comprehensively measured.

Conclusions: These trials provide strong evidence that UTT inclusive of universal testing increases population-level viral suppression and decreases HIV incidence and mortality faster than the status quo in SSA and should be adapted at a sub-country level as a public health strategy. However, more is needed, including integration of new prevention interventions into UTT, in order to reach UNAIDS HIV elimination targets.

Keywords: HIV care continuum; HIV elimination; HIV prevention; HIV testing; antiretroviral therapy; public health; universal access.

© 2020 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Figures

Figure 1
Figure 1
Universal test and treat (UTT) intervention arms: baseline and end‐of study knowledge of HIV status among persons living with HIV; “First 90” (A); Baseline and end‐of‐study persons on antiretroviral therapy (ART) among those HIV diagnosed; “Second 90” (B); Baseline and end of study viral suppression among those on ART: “Third 90” (C).
Figure 2
Figure 2
Universal test and treat (UTT) intervention arms: baseline and end of study population‐level viral suppression (A); Population‐level viral suppression from country surveys 24, 25 and in the intervention arms in the UTT trials (B) 7, 8, 9, 10.

References

    1. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al. Heterosexual HIV‐1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731):2092–8.
    1. Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population‐based study. Lancet. 2010;376(9740):532–9.
    1. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS ONE. 2010;5:e11068.
    1. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48–57.
    1. Kulkarni SP, Shah KR, Sarma KV, Mahajan AP. Clinical uncertainties, health service challenges, and ethical complexities of HIV "test‐and‐treat": a systematic review. Am J Public Health. 2013;103(6):e14–23.
    1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV‐1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
    1. Hayes RJ, Donnell D, Floyd S, Mandla N, Bwalya J, Sabapathy K, et al. Effect of universal testing and treatment on HIV incidence – HPTN 071 (PopART). N Engl J Med. 2019;381(3):207–18.
    1. Havlir DV, Balzer LB, Charlebois ED, Clark TD, Kwarisiima D, Ayieko J, et al. HIV testing and treatment with the use of a community health approach in Rural Africa. N Engl J Med. 2019;381(3):219–29.
    1. Makhema J, Wirth KE, Pretorius Holme M, Gaolathe T, Mmalane M, Kadima E, et al. Universal testing, expanded treatment, and incidence of HIV infection in Botswana. N Engl J Med. 2019;381(3):230–42.
    1. Iwuji CC, Orne‐Gliemann J, Larmarange J, Balestre E, Thiebaut R, Tanser F, et al. Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open‐label, community cluster randomised trial. Lancet HIV. 2018;5(3):e116–25.
    1. Perriat D, Balzer L, Hayes R, Lockman S, Walsh F, Ayles H, et al. Comparative assessment of five trials of universal HIV testing and treatment in sub‐Saharan Africa. J Int AIDS Soc. 2018;21:e25048.
    1. Joint United Nations Programme on HIV/AIDS . 90–90‐90–An ambitious treatment target to help end the AIDS epidemic. [Internet] Geneva, Switzerland; 2014. [cited 2019 Nov 10]. Available from:
    1. World Health Organization (WHO) . Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. [Internet] Genva, Switzerland; 2013. [cited 2019 Nov 10]. Available from:
    1. World Health Organization (WHO) . Guideline on when to start antiretroviral therapy and on pre‐exposure prophylaxis for HIV. [Internet] Geneva, Switzerland; 2015. [cited 2019 Nov 10]. Available from:
    1. The INSIGHT START Study Group . Initiation of Antiretroviral Therapy In Early Asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.
    1. Group ISS , Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.
    1. Group TAS , Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22.
    1. Chamie G, Clark TD, Kabami J, Kadede K, Ssemmondo E, Steinfeld R, et al. A hybrid mobile approach for population‐wide HIV testing in rural east Africa: an observational study. Lancet HIV. 2016;3(3):e111–9.
    1. Plazy M, Farouki KE, Iwuji C, Okesola N, Orne‐Gliemann J, Larmarange J, et al. Access to HIV care in the context of universal test and treat: challenges within the ANRS 12249 TasP cluster‐randomized trial in rural South Africa. J Int AIDS Soc. 2016;19(1):20913.
    1. Seeley J, Bond V, Yang B, Floyd S, MacLeod D, Viljoen L, et al. Understanding the time needed to link to care and start ART in seven HPTN 071 (PopART) study communities in Zambia and South Africa. AIDS Behav. 2019;23(4):929–46.
    1. Curran K, Ngure K, Shell‐Duncan B, Vusha S, Mugo NR, Heffron R, et al. 'If I am given antiretrovirals I will think I am nearing the grave': Kenyan HIV serodiscordant couples' attitudes regarding early initiation of antiretroviral therapy. AIDS. 2014;28(2):227–33.
    1. Slogrove AL, Sohn AH. The global epidemiology of adolescents living with HIV: time for more granular data to improve adolescent health outcomes. Curr Opin HIV AIDS. 2018;13(3):170–8.
    1. Brown LB, Getahun M, Ayieko J, Kwarisiima D, Owaraganise A, Atukunda M, et al. Factors predictive of successful retention in care among HIV‐infected men in a universal test‐and‐treat setting in Uganda and Kenya: A mixed methods analysis. PLoS ONE. 2019;14:e0210126.
    1. El‐Sadr WM, Mayer KH, Rabkin M, Hodder SL. AIDS in America ‐ back in the headlines at long last. N Engl J Med. 2019;380(21):1985–7.
    1. Joint United Nations Programme on HIV/AIDS . UNAIDS Data 2019 Joint United Nations Programme on HIV/AIDS. [Internet] Geneva, Switzerland; 2019. [cited 2019 Nov 10]. Available from:
    1. Jewell BL, Balzer LB, Clark TD, Charlebois ED, Maddali SR, Kamya MR, et al. Modeling Projected HIV Incidence in the SEARCH Study of Treatment as Prevention in East Africa. Abstract presented at AIDS 2018 Conference; 2018 Jul 23–27; Amsterdam, Netherlands: 2019. [cited 2019 Nov 10]. Available from:
    1. Faturiyele I, Karletsos D, Ntene‐Sealiete K, Musekiwa A, Khabo M, Mariti M, et al. Access to HIV care and treatment for migrants between Lesotho and South Africa: a mixed methods study. BMC Public Health. 2018;18(1):668.
    1. Probert W. Model Projections of the Impact of the PopART Intervention in the HPTN 071 (PopART) Study. IAS 2019 Conference; 2019 July 21‐24; Mexico City, Mexico: International AIDS Society; 2019.
    1. Kamya M, Petersen ML, Kwariisima D, Ayieko J, Sang N, Kabami J, et al. Search Intervention Reduces Mortality at a Population Level in Men with Low CD4 Count. CROI; 2019 March 7; Seattle, USA; 2019.
    1. Shade SB, Osmand T, Luo A, Aine R, Assurah E, Mwebaza B, et al. Costs of streamlined HIV care delivery in rural Ugandan and Kenyan clinics in the SEARCH study. AIDS. 2018;32(15):2179–88.
    1. Chang W, Chamie G, Mwai D, Clark TD, Thirumurthy H, Charlebois ED, et al. Implementation and operational research: cost and efficiency of a hybrid mobile multidisease testing approach with high HIV testing coverage in East Africa. J Acquir Immune Defic Syndr. 2016;73(3):e39–45.
    1. Ghebreyesus TA, Aranguren M. The world spends more money for health ‐ on the road to UHC, let's strive for better health for the money! BMJ Glob Health. 2019;4:e001522.
    1. Bekker LG, Alleyne G, Baral S, Cepeda J, Daskalakis D, Dowdy D, et al. Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society‐Lancet Commission. Lancet. 2018;392(10144):312–58.
    1. Shade SB, Osmand T, Luo A, Maddali S, Mwebaza B, Mwesigye B, et al. Cost of integrating non‐communicable disease (NCD) care into Ugandan HIV/medical clinics in the SEARCH study. IAS 2017 Conference; July 24; Paris, France; 2017.
    1. Goals Testing Model [Internet]: Avenir Health; 2019. [2019 Oct 9]. Available from:

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj